Receptor-selective vasopressin analogs: a new push for 'decatecholaminization'?

摘要

In this issue of Shock, Boucheix et al. have compared the effects of incremental doses of selepressin or arginine vaso-pressin (AVP) on systemic and coronary hemodynamics in healthy dogs (1). Selepressin (formerly known as FE202158), a relatively short-acting peptide analog of AVP, is a highly selective agonist at the vasopressin V_(1a) receptor (2). The authors report that both selepressin and AVP increased blood pressure and decreased heart rate, which was associated with a comparable fall in both aortic and coronary blood flow. Maximal systolic contraction (dp/dt_(max)) was not significantly affected, whereas the frequency-independent relaxation constant tau was increased. Overall, there was no significant dose-effect difference between the two molecules.